Patents by Inventor Maksim Osipov

Maksim Osipov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, compositions and methods
    Patent number: 12139478
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 12, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney
  • Kinase inhibitors and uses thereof
    Patent number: 12129263
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 29, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 12091392
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: September 17, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20240254132
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: July 15, 2022
    Publication date: August 1, 2024
    Inventors: Alex L. Bagdasarian, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Benjamin J. Huffman, Katrina W. Lexa, Maksim Osipov, Arun Thottumkara
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20240140919
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 2, 2024
    Inventors: Robert A. Craig II, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Tottumkara
  • Compounds, compositions and methods
    Patent number: 11958840
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Immunoregulatory agents
    Patent number: 11932601
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo
  • Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation
    Patent number: 11919863
    Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 5, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Albert J. Delmonte, Benjamin M. Cohen, Kenneth Joseph Fraunhoffer, Sergei Kolotuchin, Francisco Gonzalez-Bobes, Gregory Louis Beutner, Adam Joseph Freitag, Michael Scott Bultman, Yu Fan, Prantik Maity, Ian Scott Young, Hilary Plake Beck, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20230416205
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 28, 2023
    Inventors: Alex L. Bagdasarian, Cyril Bucher, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 11851433
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: October 5, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11851440
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: December 26, 2023
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230357162
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: August 13, 2021
    Publication date: November 9, 2023
    Inventors: Alex L. Bagdasarian, Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Benjamin J. Huffman, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230348437
    Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
    Type: Application
    Filed: July 1, 2021
    Publication date: November 2, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Brian M. Fox, Cheng Hu, Katrina W. Lexa, Lizanne G. Nilewski, Maksim Osipov, Arun Thottumkara
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20230250072
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20230114472
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 23, 2022
    Publication date: April 13, 2023
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Publication number: 20220411433
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: December 29, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • IMMUNOREGULATORY AGENTS
    Publication number: 20220274926
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: December 16, 2021
    Publication date: September 1, 2022
    Inventors: Hilary Plake BECK, Juan Carlos JAEN, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY, James Aaron BALOG, David K. WILLIAMS, Weiwei GUO
  • SUBSTITUTED QUINOLINYLCYCLOHEXYLPROPANAMIDE COMPOUNDS AND IMPROVED METHODS FOR THEIR PREPARATION
    Publication number: 20220267273
    Abstract: The disclosure is directed to improved methods for preparing substituted quinolinylcyclohexylpropanamide compounds.
    Type: Application
    Filed: December 16, 2021
    Publication date: August 25, 2022
    Inventors: Albert J. DELMONTE, Benjamin M. COHEN, Kenneth Joseph FRAUNHOFFER, Sergei KOLOTUCHIN, Francisco GONZALEZ-BOBES, Gregory Louis BEUTNER, Adam Joseph FREITAG, Michael Scott BULTMAN, Yu FAN, Prantik MAITY, Ian Scott YOUNG, Hilary Plake BECK, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20220177456
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 9, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20220177438
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: February 12, 2020
    Publication date: June 9, 2022
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara